Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a strong sell rating to a sell rating in a research note published on Sunday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

Arcturus Therapeutics Trading Up 6.7%

Arcturus Therapeutics stock opened at $7.52 on Friday. The firm has a market capitalization of $213.72 million, a price-to-earnings ratio of -2.27 and a beta of 2.39. The firm’s fifty day moving average price is $6.75 and its two-hundred day moving average price is $7.39. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.16. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. The company had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. On average, research analysts forecast that Arcturus Therapeutics will post -3.55 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. boosted its position in shares of Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 738 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in Arcturus Therapeutics by 27.5% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,567 shares during the period. Bank of America Corp DE increased its holdings in Arcturus Therapeutics by 0.7% during the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after acquiring an additional 2,098 shares during the period. BNP Paribas Financial Markets lifted its stake in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock worth $1,644,000 after purchasing an additional 2,857 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.